Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;7(2):570-6.
doi: 10.1007/s12072-012-9387-y. Epub 2012 Jul 3.

Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety

Vincenzo Gianturco  1 , Giovanni Troisi  2 , Alessia Bellomo  1 , Sciaila Bernardini  1 , Elisa D'Ottavio  1 , Valeria Formosa  1 , Cristina Lo Iacono  1 , Walter Verrusio  1 , Benedetta Marigliano  1 , Vincenzo Marigliano  1
Affiliations

Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety

Vincenzo Gianturco et al. Hepatol Int. 2013 Jun.

Abstract

Background and purpose: Nonalcoholic fatty liver disease (NAFLD) is one of the causes of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome. The purpose of the present study was to evaluate the impact of combination therapy with alpha-lipoic acid (ALA) and ursodeoxycholic acid (UDCA) on NAFLD.

Methods: Alpha-lipoic acid 400 mg/day plus UDCA 300 mg/day (ALAUDCA) was investigated in patients over a period of 12 months using a randomized, placebo (PLA)-controlled study with four parallel groups. Serum concentration of gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin and platelets (PLT) were measured at the beginning and at the end of the treatment. Moreover, the AST/ALT ratio and the NAFLD fibrosis score were examined.

Results: A total of 120 patients were randomly assigned to the four groups. ALA and UDCA were safe and well tolerated in the oral daily administration only. AST, ALT, GGT (p < 0.001) showed a significant difference between ALAUDCA and other three groups. Besides, NAFLD fibrosis score underlined a significant reduction (p < 0.04) in the ALAUDCA group, while AST/ALT ratio presented a moderate decline (p > 0.05).

Conclusion: ALAUDCA therapy reduced AST, ALT, GGT values and improved NAFLD fibrosis score and AST/ALT ratio, especially in patients who were on a hypocaloric diet. These findings will be useful in patient selection in future clinical trials with ALAUDCA in long-term studies.

Keywords: Alpha-lipoic acid; NAFLD; Nonalcoholic fatty liver disease; Ursodeoxycholic acid.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Am J Gastroenterol. 1999 Sep;94(9):2467-74 - PubMed
    1. Life Sci. 2012 Jan 30;90(5-6):200-5 - PubMed
    1. Arch Gerontol Geriatr. 2009;49 Suppl 1:129-33 - PubMed
    1. J Insur Med. 2004;36(1):27-41 - PubMed
    1. Science. 2006 Aug 25;313(5790):1137-40 - PubMed

LinkOut - more resources